Switch theme
Sign up to access all valuation multiples
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
1988
96
LTM Revenue $61.3M
LTM EBITDA $8.6M
$507M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Delcath Systems has a last 12-month revenue (LTM) of $61.3M and a last 12-month EBITDA of $8.6M.
In the most recent fiscal year, Delcath Systems achieved revenue of $37.2M and an EBITDA of -$12.2M.
Delcath Systems expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Delcath Systems valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $61.3M | XXX | $37.2M | XXX | XXX | XXX |
| Gross Profit | $52.0M | XXX | $31.0M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $8.6M | XXX | -$12.2M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | -33% | XXX | XXX | XXX |
| EBIT | -$6.6M | XXX | -$12.4M | XXX | XXX | XXX |
| EBIT Margin | -11% | XXX | -33% | XXX | XXX | XXX |
| Net Profit | -$14.4M | XXX | -$26.4M | XXX | XXX | XXX |
| Net Margin | -24% | XXX | -71% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Delcath Systems's stock price is $16.
Delcath Systems has current market cap of $565M, and EV of $507M.
See Delcath Systems trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $507M | $565M | XXX | XXX | XXX | XXX | $-0.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Delcath Systems has market cap of $565M and EV of $507M.
Delcath Systems's trades at 13.6x EV/Revenue multiple, and -41.6x EV/EBITDA.
Equity research analysts estimate Delcath Systems's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Delcath Systems has a P/E ratio of -39.1x.
See valuation multiples for Delcath Systems and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $565M | XXX | $565M | XXX | XXX | XXX |
| EV (current) | $507M | XXX | $507M | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 13.6x | XXX | XXX | XXX |
| EV/EBITDA | 58.9x | XXX | -41.6x | XXX | XXX | XXX |
| EV/EBIT | -76.3x | XXX | -40.8x | XXX | XXX | XXX |
| EV/Gross Profit | 9.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -39.1x | XXX | -21.4x | XXX | XXX | XXX |
| EV/FCF | -151.0x | XXX | -26.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDelcath Systems's last 12 month revenue growth is 82%
Delcath Systems's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Delcath Systems's rule of 40 is -2150% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Delcath Systems's rule of X is 220% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Delcath Systems and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 82% | XXX | 91% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | -33% | XXX | XXX | XXX |
| EBITDA Growth | 289% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2150% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 220% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 117% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Delcath Systems acquired XXX companies to date.
Last acquisition by Delcath Systems was XXXXXXXX, XXXXX XXXXX XXXXXX . Delcath Systems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Delcath Systems founded? | Delcath Systems was founded in 1988. |
| Where is Delcath Systems headquartered? | Delcath Systems is headquartered in United States of America. |
| How many employees does Delcath Systems have? | As of today, Delcath Systems has 96 employees. |
| Who is the CEO of Delcath Systems? | Delcath Systems's CEO is Mr. Gerard J. Michel. |
| Is Delcath Systems publicy listed? | Yes, Delcath Systems is a public company listed on NAS. |
| What is the stock symbol of Delcath Systems? | Delcath Systems trades under DCTH ticker. |
| When did Delcath Systems go public? | Delcath Systems went public in 2000. |
| Who are competitors of Delcath Systems? | Similar companies to Delcath Systems include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Delcath Systems? | Delcath Systems's current market cap is $565M |
| What is the current revenue of Delcath Systems? | Delcath Systems's last 12 months revenue is $61.3M. |
| What is the current revenue growth of Delcath Systems? | Delcath Systems revenue growth (NTM/LTM) is 82%. |
| What is the current EV/Revenue multiple of Delcath Systems? | Current revenue multiple of Delcath Systems is 8.3x. |
| Is Delcath Systems profitable? | Yes, Delcath Systems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Delcath Systems? | Delcath Systems's last 12 months EBITDA is $8.6M. |
| What is Delcath Systems's EBITDA margin? | Delcath Systems's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Delcath Systems? | Current EBITDA multiple of Delcath Systems is 58.9x. |
| What is the current FCF of Delcath Systems? | Delcath Systems's last 12 months FCF is -$3.4M. |
| What is Delcath Systems's FCF margin? | Delcath Systems's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of Delcath Systems? | Current FCF multiple of Delcath Systems is -151.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
